Endothelial activation and stress index predicts 28-day mortality in patients undergoing CRRT

内皮激活和应激指数可预测接受连续性肾脏替代治疗(CRRT)患者的28天死亡率。

阅读:2

Abstract

The endothelial activation and stress index (EASIX) is recognized as a prognostic indicator across various diseases; however, its utility in patients undergoing continuous renal replacement therapy (CRRT) is limited. This study aimed to investigate the relationship between EASIX and prognosis in individuals receiving CRRT. Data from patients receiving CRRT were extracted from the Medical Information Mart for Intensive Care IV database. EASIX was calculated and log2-transformed. Kaplan-Meier survival analysis was conducted based on log2(EASIX) quartiles. Cox proportional hazards regression was utilized to estimate the relationship between EASIX and 28-day all-cause mortality. Potential nonlinear associations were evaluated through restricted cubic splines (RCS) analysis, and subgroup analyses were performed to assess the robustness of EASIX's impact on all-cause mortality. A total of 2,873 ICU patients treated with CRRT were enrolled. Kaplan-Meier analysis revealed that higher EASIX scores were significantly associated with lower 28-day survival (log-rank p < 0.001). After adjusting for confounding factors, EASIX remained significantly associated with the risk of 28-day all-cause mortality among CRRT patients (HR: 1.066; 95% CI: 1.026-1.107; p = 0.001). The area under the curve (AUC) of the SOFA+EASIX model was 0.694 (95% CI: 0.673-0.714; p < 0.001), slightly higher than that of the SOFA scores alone. These results suggest that EASIX may enhance the predictive performance of SOFA scores. RCS analysis indicated a linear association between log2(EASIX) and 28-day all-cause mortality (p for overall = 0.001; p for nonlinear = 0.224). Subgroup analyses confirmed the robustness of this association across various patient groups. In conclusion, EASIX is independently associated with mortality in patients undergoing CRRT. Prospective studies are warranted to further explore its therapeutic and prognostic significance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。